ArticleInfection2026
Hemoptysis in a patient with MDR-tuberculosis: successful diagnosis with photon counting CT and embolization of a Rasmussen aneurysm.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant tuberculosis (MDR-TB) remains a significant clinical challenge and may be complicated by life-threatening hemoptysis. One rare but serious cause of hemoptysis in TB patients is the development of pulmonary artery pseudoaneurysms, known as Rasmussen aneurysms, which typically arise within or adjacent to tuberculous cavitary lesions. CASE PRESENTATION: We report the case of a 57-year-old male patient who was diagnosed with MDR-TB in July 2024, confirmed by phenotypic resistance against rifampicin and isoniazid. According to WHO recommendations treatment with the BPaLM regimen (bedaquiline, pretomanid, linezolid, and moxifloxacin) was initiated in early August 2024 and was administered according to an extended 9-month schedule due to clinical considerations. After approximately seven months of therapy, the patient was re-hospitalized in March 2025 due to hemoptysis. A thoracic photon counting CT scan revealed regressing bilateral cavitary lesions. During the same month, a pseudoaneurysm arising from a subsegmental pulmonary artery within a cavity-consistent with a Rasmussen aneurysm-was identified. Successful embolization of the feeding vessel was performed under angiographic guidance. Post-interventional bronchoscopy showed minimal residual bloody secretions at the embolization site but no evidence of active bleeding after thorough irrigation. At that time, pending cultures for M. tuberculosis finally converted negative. The patient recovered well, and no further hemoptysis occurred.
conclusionsThis case highlights the importance of considering Rasmussen aneurysms as a potential cause of hemoptysis in patients with cavitary MDR-TB, even several months after starting antibiotic therapy. Prompt imaging-based diagnosis and endovascular intervention are critical to avoid life-threatening complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.